Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2591258 | 0.74 | GAA (0.49) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL6755229 | 0.73 | HTT (0.44) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL4045244 | 0.73 | HTT (0.44) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL2383891 | 0.73 | HTT (0.44) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL9125151 | 0.72 | HTT (0.41) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL9734970 | 0.72 | HTT (0.41) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL31531675 | 0.71 | HTT (0.40) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL633115 | 0.70 | HTT (0.42) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL25836668 | 0.70 | HTT (0.42) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL13208612 | 0.70 | HTT (0.42) | HTTGAAKDM4ETSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228465-A1 | SUBSTITUTED PYRIDINE N-OXIDE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| US-11919881-B2 | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-05 | — | — | US | disclosed |
| US-20220315561-A1 | SUBSTITUTED PYRIDINE N-OXIDE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| US-6503935-B1 | Treating urinary incontinence or retrograde ejaculation | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
| EP-1259491-A1 | 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS | Abbott Laboratories (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060802-A1 | 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES, AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS | ABBOTT LABORATORIES (US) | 2001-08-23 | — | — | WO | disclosed |
| EP-1102754-A1 | IMIDAZOLES AND RELATED COMPOUNDS AS ALPHA-1A AGONISTS | ABBOTT LABORATORIES (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007997-A1 | IMIDAZOLES AND RELATED COMPOUNDS AS α1A AGONISTS | ABBOTT LABORATORIES (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228465-A1 | SUBSTITUTED PYRIDINE N-OXIDE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS | F11, F2, KLKB1 | HTT 4812/4885GAA 3656/4885KDM4E 729/4885 |
| US-11919881-B2 | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors | F11, F2, KLKB1 | HTT 4812/4885GAA 3656/4885KDM4E 729/4885 |
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | HTT 4621/4885GAA 2831/4885KDM4E 823/4885 |
| US-20220315561-A1 | SUBSTITUTED PYRIDINE N-OXIDE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS | F11, F2, KLKB1 | HTT 4812/4885GAA 3656/4885KDM4E 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.